Less time for
LESS TIME FOR DIAGNOSIS, MORE TIME FOR LIFE
It will take the misery
“It will take the misery out of waiting for the diagnosis which, would have given us two less days of agony”
It will take the misery
成立于2017年,位于博洛尼亚,OaCP是一家提供化学试剂以减少癌症基因诊断检测的时间(-97%)和成本(-50%)的意大利公司。公司的核心产品(Rapid-ISH和Smart-ISH杂交缓冲液)和辅助设备(Titan FISH探针)都已通过可行性验证,并获得欧盟CE-IVD认证。此外,OaCP探针也已通过CFDA认证。OaCP 技术已在欧盟,美国,中国和印度申请了专利,享有知识产权保护。

独自の試薬により精度を維持しながら癌の診断までの時間を72時間から2時間に短縮。コストも低減。
previous arrow
next arrow

DoMo Genetics

HOW DOES IT WORK?

Fast

WE REDUCE TEST TIME FROM 3 DAYS TO ONLY 2 HOURS

Easy to use

YOU DON’T CHANGE YOUR PROTOCOL, YOU SIMPLY ADD WITH THE PROBE

Affordable

WE REDUCE THE COSTS UP TO 50%

Tutorials

SEE OUR PROTOCOLS FOR FFPE TISSUES: FAST AND UNIVERSAL FISH

Among the many miseries cancer brings, the anguish of waiting for a diagnosis is one of the worst. We kill some of this misery by majorly reducing the time for diagnostic tests.

Our objective is to provide oncology diagnostics laboratories and research institution with solutions that will disrupt cancer diagnosis times and cost.

Our Products

COVID-19

ONCOLOGY

GLOBAL HEALTH

INSTRUMENT

INSIGHTS

OaCP has reached the 2nd place in the 5th China (Shenzhen) Innovation & Entrepreneurship International Competition

OaCP has been awarded with the 2nd prize of the 5th China (Shenzhen) Innovation & Entrepreneurship International Competition. The "Fly With Shenzhen" competition aims at integrating innovation and entrepreneurship resources, assisting overseas innovation and...

OaCP in the top 5 Big Health companies of the China Overseas Talent Innovation and Entrepreneurship Competition

OaCP has won the 4th prize within the Big Health area of expertise of the China Overseas Talent Innovation and Entrepreneurship Competition promoted by Wuhan City. The competition is hosted by China Association for Science and Technology (CAST), People's Government of...

RT- PCR, the gold standard in CoViD-19 diagnosis: the most common pitfalls and their interpretations

The gold standard for SARS-CoV-2 diagnosis is the Reverse Transcriptase Polymerase Chain Reaction, aka RT-PCR or qRT-PCR. This technique has been introduced in 1983 (Saiki et al. 1985) and nowadays is widely used in the diagnosis of many pathologies, from infectious...

OaCP has made it to the Go Global Finals

The Judging Panel of the Go Global Awards has announced that OACP IE LTD has made the short-list for the Go Global Awards as Start-Up Exporter of the Year. Learn more on https://www.zghcl.net/chuangye/index-e.html THE GO GLOBAL AWARDS The International Trade Council’s...

Dai test oncologici ai tamponi rapidi, l’innovazione è nel nostro DNA

Intervista rilasciata dal nostro CEO Enrico Di Oto a Marco Bettazzi per la Repubblica Bologna, sezione Economia - 30 agosto 2021 Tra febbraio e marzo hanno sviluppato il primo tampone rapido al mondo per individuare le varianti del Covid, in collaborazione con una...

Delta Variant outbreak emergency: what and where

As the media have been writing for weeks, the DELTA variant (born as variant B.1.617.2), first identified in mid-2020, is spreading fast. According to last ECDC commentary, the highly infectious variant of concern (V.O.C.) DELTA is becoming  “dominant in much of the...

OaCP has been selected for the China Overseas Talent Innovation and Entrepreneurship Competition

OaCP has been selected for the China Overseas Talent Innovation and Entrepreneurship Competition promoted by Wuhan City. The competition is hosted by China Association for Science and Technology (CAST), People's Government of Hubei Province, and organized by: Hubei...

OaCP su Forbes: Un kit per ripartire

Abbiamo raccontato la nostra storia a Forbes che ha deciso di inserirci nel loro speciale Healthcare di luglio. Con tutto il lavoro che stiamo facendo, sia sul fronte oncologico che su quello Covid-19, per essere sempre un passo avanti rispetto ai problemi che...

OaCP has been selected by InvestHorizon to join its accelerator programme

We've been selected by Invest Horizon Accelerator to join their accelerator Program, financed by the European Commission, in association with Eureka, to facilitate Series A funding for selected deep tech companies boosting their investment readiness and investor...

First in vivo evidence of escape of SARS-CoV-2 South Africa variant from natural and vaccine-induced sera

Months after the first SARS-CoV-2 variant has been sequenced, many scientific works have largely hypothesized the clinical impact of the mutations, based on in silico experiments. Starting point The role of SARS-CoV-2 mutations has been supposed to impact the immune...